Deep learning-enhanced chemiluminescence vertical flow assay for high-sensitivity cardiac troponin I testing
Fuente:
arXiv
Salvato in:
| Autori principali: | , , , , , , , , , , , , , |
|---|---|
| Natura: | Preprint |
| Pubblicazione: |
2024
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866929699918184448 |
|---|---|
| author | Han, Gyeo-Re Goncharov, Artem Eryilmaz, Merve Ye, Shun Joung, Hyou-Arm Ghosh, Rajesh Ngo, Emily Tomoeda, Aoi Lee, Yena Ngo, Kevin Melton, Elizabeth Garner, Omai B. Di Carlo, Dino Ozcan, Aydogan |
| author_facet | Han, Gyeo-Re Goncharov, Artem Eryilmaz, Merve Ye, Shun Joung, Hyou-Arm Ghosh, Rajesh Ngo, Emily Tomoeda, Aoi Lee, Yena Ngo, Kevin Melton, Elizabeth Garner, Omai B. Di Carlo, Dino Ozcan, Aydogan |
| contents | Democratizing biomarker testing at the point-of-care requires innovations that match laboratory-grade sensitivity and precision in an accessible format. Here, we demonstrate high-sensitivity detection of cardiac troponin I (cTnI) through innovations in chemiluminescence-based sensing, imaging, and deep learning-driven analysis. This chemiluminescence vertical flow assay (CL-VFA) enables rapid, low-cost, and precise quantification of cTnI, a key cardiac protein for assessing heart muscle damage and myocardial infarction. The CL-VFA integrates a user-friendly chemiluminescent paper-based sensor, a polymerized enzyme-based conjugate, a portable high-performance CL reader, and a neural network-based cTnI concentration inference algorithm. The CL-VFA measures cTnI over a broad dynamic range covering six orders of magnitude and operates with 50 uL of serum per test, delivering results in 25 min. This system achieves a detection limit of 0.16 pg/mL with an average coefficient of variation under 15%, surpassing traditional benchtop analyzers in sensitivity by an order of magnitude. In blinded validation, the computational CL-VFA accurately measured cTnI concentrations in patient samples, demonstrating a robust correlation against a clinical-grade FDA-cleared analyzer. These results highlight the potential of CL-VFA as a robust diagnostic tool for accessible, rapid cardiac biomarker testing that meets the needs of diverse healthcare settings, from emergency care to underserved regions. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2412_08945 |
| institution | arXiv |
| publishDate | 2024 |
| record_format | arxiv |
| spellingShingle | Deep learning-enhanced chemiluminescence vertical flow assay for high-sensitivity cardiac troponin I testing Han, Gyeo-Re Goncharov, Artem Eryilmaz, Merve Ye, Shun Joung, Hyou-Arm Ghosh, Rajesh Ngo, Emily Tomoeda, Aoi Lee, Yena Ngo, Kevin Melton, Elizabeth Garner, Omai B. Di Carlo, Dino Ozcan, Aydogan Medical Physics Applied Physics Biological Physics Democratizing biomarker testing at the point-of-care requires innovations that match laboratory-grade sensitivity and precision in an accessible format. Here, we demonstrate high-sensitivity detection of cardiac troponin I (cTnI) through innovations in chemiluminescence-based sensing, imaging, and deep learning-driven analysis. This chemiluminescence vertical flow assay (CL-VFA) enables rapid, low-cost, and precise quantification of cTnI, a key cardiac protein for assessing heart muscle damage and myocardial infarction. The CL-VFA integrates a user-friendly chemiluminescent paper-based sensor, a polymerized enzyme-based conjugate, a portable high-performance CL reader, and a neural network-based cTnI concentration inference algorithm. The CL-VFA measures cTnI over a broad dynamic range covering six orders of magnitude and operates with 50 uL of serum per test, delivering results in 25 min. This system achieves a detection limit of 0.16 pg/mL with an average coefficient of variation under 15%, surpassing traditional benchtop analyzers in sensitivity by an order of magnitude. In blinded validation, the computational CL-VFA accurately measured cTnI concentrations in patient samples, demonstrating a robust correlation against a clinical-grade FDA-cleared analyzer. These results highlight the potential of CL-VFA as a robust diagnostic tool for accessible, rapid cardiac biomarker testing that meets the needs of diverse healthcare settings, from emergency care to underserved regions. |
| title | Deep learning-enhanced chemiluminescence vertical flow assay for high-sensitivity cardiac troponin I testing |
| topic | Medical Physics Applied Physics Biological Physics |
| url | https://arxiv.org/abs/2412.08945 |